Potency, selectivity, and consequences of nonselectivity of PDE inhibition-Reference-Cited by-同舟云学术

Potency, selectivity, and consequences of nonselectivity of PDE inhibition

Published:2004-06 Issue:S1 Volume:16 Page:S11-S14
ISSN:0955-9930
Container-title:International Journal of Impotence Research
language:en
Short-container-title:Int J Impot Res

Author:

Bischoff E

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://www.nature.com/articles/3901208.pdf

Reference12 articles.

1. Saenz de Tejada I et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–290.

2. Porst H . IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14(Suppl 1): S57–S64.

3. Turko IV, Ballard SA, Francis SH, Corbin JD . Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56: 124–130.

4. Saenz de Tejada I, Frutos JA, Gaudo M, Florio V . Comparative selectivity: profiles of tadalafil, sildenafil and vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res 2002; 14(Suppl 4): S20–S32.

5. Corbin JD, Francis SH . Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 277: 47581–47587.

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. siRNA Targeting PDE5A Partially Restores Vascular Damage Due to Type 1 Diabetes in a Streptozotocin-Induced Rat Model;Scientia Pharmaceutica;2023-11-08

2. Optimizing metabolic stability of phosphodiesterase 5 inhibitors: Discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity;Bioorganic & Medicinal Chemistry Letters;2023-08

3. Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis;Value in Health Regional Issues;2023-07

4. Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease;Pharmaceutics;2022-09-07

5. Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway;Lung;2022-08-30